Table 1. Effect of Drs B2 on proliferation of human tumor and non tumor cells.

	Cell name	Cell type	GI50
			[µM of Drs B2 ± SD]
tumor	PC3	prostate adenocarcinoma	1.24±0.23
	LNCAP	prostate adenocarcinoma (adrenogen sensitive)	0.31±0.15
	DU145	prostate carcinoma (non adrenogen sensitive)	0.91±0.04
	MDA-MB231	mammary carcinoma	8.06±0.50
	RAJI	B-lymphoma	2.57±0.75
immortalized	LB-EBV	B-lymphoblastoids, transformed by Epstein-Barr virus	1.09±0.56
	HTK	corneal fibroblasts	1.80±0.40
	PNT1A	prostatic cell line (non adrenogen sensitive)	0.38±0.05
primary	G1947	stromal prostate fibroblasts	*
	FD	skin fibroblasts	*

All the cells used are from human origin, the names of cell lines or types and their tissues of origin are indicated. Proliferation of each cell type was performed in plastic 24 wells plates (1.91 cm²; cell density of 1×10⁴ cells/well/0.5 mL). On the first, third and fifth day after plating the cells were treated with Drs B2 at different concentrations ranging from 0 till 15 µM. Twenty four hours after the last treatment cell counting was performed with crystal violet staining for adherent cells and with a Malassez Hemacytometer for non-adherent cells. Results are represented in peptide concentration inhibiting 50% of the cell growth GI50 ± SD of at least three determinations.

^*No cytotoxicity observed when cells were treated with a maximal concentration of 15 µM of Drs B2.